Crossmark

Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case report

Crossref DOI link: https://doi.org/10.1186/s12885-020-6516-1

Published Online: 2020-01-15

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Connell, Claire M.

Brais, Rebecca

Whitaker, Hayley

Upponi, Sara

Beh, Ian

Risdall, Jane

Corrie, Pippa

Janowitz, Tobias

Jodrell, Duncan I. https://orcid.org/0000-0001-9360-1670
Funding

Funding for this research was provided by:

Cambridge Experimental Medicine Initiative

Cancer Research United Kingdom
License Information

Text and Data Mining valid from 2020-01-15

Version of Record valid from 2020-01-15
More Information

Article History

Received: 22 March 2019

Accepted: 6 January 2020

First Online: 15 January 2020

Ethics approval and consent to participate

: Verbal informed consent was provided from the patient described in this case report, and written consent was provided from their next of kin.

: The patient died prior to publication. Written informed consent was obtained from the patient’s next of kin, which is available for review by the Editor.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below